|
Status |
Public on Oct 10, 2014 |
Title |
MLL-AF9-GFP_DMSO_D5_4 |
Sample type |
RNA |
|
|
Source name |
MLL-AF9-GFP_DMSO_D5
|
Organism |
Mus musculus |
Characteristics |
strain background: Balb/c cell line: MLL-AF9-IRES-GFP cell type: transformed murine leukemia progenitor cell line treated with: DMSO
|
Treatment protocol |
Treatment with 3μM of the indicated compounds for 4-5 days, or induction of gene-specific shRNAs (with an inducible TRMPVIR system) for 6 days, followed by total RNA preparation for microarray.
|
Growth protocol |
Transformed murine leukemia progenitor cell lines were cultured in Opti-MEM base medium supplemented with 10% FBS, 1% antibiotics, 50 μM mercaptoethanol and stem cell factor
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated with the Rneasy Plus Miniprep Kit (Qiagen).
|
Label |
Biotin
|
Label protocol |
The cDNA was fragmented and terminally labeled with biotin, using the Affymetrix GeneChip WT Terminal Labeling kit (Affymetrix, Santa Clara, CA)
|
|
|
Hybridization protocol |
Samples were hybridized with Affymetrix Mouse Gene 2.1 ST Array Strip (Affymetrix) according to the manifacture's instruction.
|
Scan protocol |
Standard Affymetrix protocol
|
Description |
MLL-AF9-puro_DMSO_D5_4
|
Data processing |
Hybridization signals were retrieved and normalized, followed by differential expression analysis and statistical analysis using GeneSpring Analysis Platform GX 12.6 (Agilent Technologies). probe group file: MoGene-2_1-st.pgf meta-probeset file: MoGene-2_1-st.mps
|
|
|
Submission date |
Oct 09, 2014 |
Last update date |
Oct 10, 2014 |
Contact name |
Bowen Xu |
E-mail(s) |
bowenx@email.unc.edu
|
Phone |
919-966-5953
|
Organization name |
UNC-Chapel Hill
|
Department |
Biochemistry and Biophysics
|
Lab |
Wang
|
Street address |
450 West Drive, CB7295, Lineberger Cancer Center, GREG WANG Lab, RM 31-331
|
City |
Chapel Hill |
State/province |
NC |
ZIP/Postal code |
27599 |
Country |
USA |
|
|
Platform ID |
GPL17400 |
Series (1) |
GSE62198 |
Expression data of MLL-AF9-transformed murine leukemia progenitor cells, following treatment with UNC1999, a dual Ezh1 and Ezh2 inhibitor, or knockdown of EED |
|